FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2314906058> ?p ?o ?g. }

• W2314906058 abstract "Background The order of use of biologic agents after failing a TNF inhibitor is still a question for debate. Phase III trial data in TNF-IR patients show comparable efficacy results across biologic agents and limited head-to-head studies have been published. Prospective registries offer a unique opportunity to observe the effectiveness (combined evaluation of efficacy and safety profile over time) of these agents in a clinical setting. Objectives To evaluate if patients with rheumatoid arthritis (RA) treated with rituximab (RIT) after failing a first or a second anti-TNF agents (TNF-IR) have a different drug retention rate than patients similarly prescribed anti-TNF agents (pooled adalimumab, etanercept or infliximab) and compare the treatment strategies of using RIT as second or third biologic treatment. Methods Data from TNF-IR RA patients prescribed adalimumab (ADA), etanercept (ETA), infliximab (INF) or rituximab (RIT) as second or third biologic agents on or after January 1st 2007 was extracted and subjects taking either ADA, ETA or INF were pooled to form the anti-TNF cohort. Baseline demographics included age, disease duration, HAQ-DI, fatigue and pain visual analog scale evaluations (VAS), TJC, SJC, DAS 28 ESR and SDAI. Five-year drug retention rates were estimated and compared using Kaplan-Meier survival estimates. Statistical analysis was performed using SAS version 9.3. RHUMADATA® is a clinical database and registry used in daily clinical practice at the IRM and CORQ. Results The data from 226 RA patients were extracted, 153 and 73 having respectively failed a first and a second anti-TNF agent. No clinically significant differences in baseline variables were observed between treatment groups in second and third intention. The 5 year retention rates of second line RIT and anti-TNF use were 74% and 36% respectively (Log-rank p=0.002). In patients having failed two anti-TNF, subsequent use of RIT and anti-TNF agents respectively demonstrated 5 year retention rates of 48% and 24% (Log-rank p=0.004). Although numerically superior (74% vs 48%) second line use of RIT did not reach statistical difference when compared to third line usage. Conclusions As a second line agent, in TNF-IR patients, RIT demonstrates a better 5 year retention rate than anti-TNF agents. As third line therapy, RIT is also statistically superior to anti-TNF agents. Although no statistical difference was demonstrated between second and third line RIT use, it is evident that positioning RIT as second line offers a better long term outcome. References S.M. Du Pan, A. Scherer, C. Gabay, A. Finckh. Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Annals of the rheumatic diseases 01/2012; 71(6):997-9. Acknowledgements The Rhumadata clinical database and registry is supported by unrestricted grant from Abbvie Canada, Amgen Canada, BMS Canada, Pfizer Canada, Roche Canada. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.1890" @default.
• W2314906058 created "2016-06-24" @default.
• W2314906058 creator A5024888633 @default.
• W2314906058 creator A5030150540 @default.
• W2314906058 creator A5033216700 @default.
• W2314906058 creator A5039465328 @default.
• W2314906058 creator A5045553134 @default.
• W2314906058 creator A5046495503 @default.
• W2314906058 creator A5054685224 @default.
• W2314906058 creator A5067384254 @default.
• W2314906058 creator A5087602901 @default.
• W2314906058 creator A5087628761 @default.
• W2314906058 date "2014-06-01" @default.
• W2314906058 modified "2023-09-24" @default.
• W2314906058 title "AB0235 Use of Rituximab Compared to Anti-TNF Agents as Second and Third Line Therapy in Patients with Rheumatoid Arthritis. A Report from the Rhumadata® Clinical Database and Registry" @default.
• W2314906058 doi "https://doi.org/10.1136/annrheumdis-2014-eular.1890" @default.
• W2314906058 hasPublicationYear "2014" @default.
• W2314906058 type Work @default.
• W2314906058 sameAs 2314906058 @default.
• W2314906058 citedByCount "0" @default.
• W2314906058 crossrefType "journal-article" @default.
• W2314906058 hasAuthorship W2314906058A5024888633 @default.
• W2314906058 hasAuthorship W2314906058A5030150540 @default.
• W2314906058 hasAuthorship W2314906058A5033216700 @default.
• W2314906058 hasAuthorship W2314906058A5039465328 @default.
• W2314906058 hasAuthorship W2314906058A5045553134 @default.
• W2314906058 hasAuthorship W2314906058A5046495503 @default.
• W2314906058 hasAuthorship W2314906058A5054685224 @default.
• W2314906058 hasAuthorship W2314906058A5067384254 @default.
• W2314906058 hasAuthorship W2314906058A5087602901 @default.
• W2314906058 hasAuthorship W2314906058A5087628761 @default.
• W2314906058 hasConcept C126322002 @default.
• W2314906058 hasConcept C14184104 @default.
• W2314906058 hasConcept C17991360 @default.
• W2314906058 hasConcept C1862650 @default.
• W2314906058 hasConcept C198451711 @default.
• W2314906058 hasConcept C2777138892 @default.
• W2314906058 hasConcept C2777226972 @default.
• W2314906058 hasConcept C2777575956 @default.
• W2314906058 hasConcept C2779338263 @default.
• W2314906058 hasConcept C2779722408 @default.
• W2314906058 hasConcept C2780132546 @default.
• W2314906058 hasConcept C2780653079 @default.
• W2314906058 hasConcept C41008148 @default.
• W2314906058 hasConcept C535046627 @default.
• W2314906058 hasConcept C71924100 @default.
• W2314906058 hasConcept C72563966 @default.
• W2314906058 hasConcept C77088390 @default.
• W2314906058 hasConceptScore W2314906058C126322002 @default.
• W2314906058 hasConceptScore W2314906058C14184104 @default.
• W2314906058 hasConceptScore W2314906058C17991360 @default.
• W2314906058 hasConceptScore W2314906058C1862650 @default.
• W2314906058 hasConceptScore W2314906058C198451711 @default.
• W2314906058 hasConceptScore W2314906058C2777138892 @default.
• W2314906058 hasConceptScore W2314906058C2777226972 @default.
• W2314906058 hasConceptScore W2314906058C2777575956 @default.
• W2314906058 hasConceptScore W2314906058C2779338263 @default.
• W2314906058 hasConceptScore W2314906058C2779722408 @default.
• W2314906058 hasConceptScore W2314906058C2780132546 @default.
• W2314906058 hasConceptScore W2314906058C2780653079 @default.
• W2314906058 hasConceptScore W2314906058C41008148 @default.
• W2314906058 hasConceptScore W2314906058C535046627 @default.
• W2314906058 hasConceptScore W2314906058C71924100 @default.
• W2314906058 hasConceptScore W2314906058C72563966 @default.
• W2314906058 hasConceptScore W2314906058C77088390 @default.
• W2314906058 hasLocation W23149060581 @default.
• W2314906058 hasOpenAccess W2314906058 @default.
• W2314906058 hasPrimaryLocation W23149060581 @default.
• W2314906058 isParatext "false" @default.
• W2314906058 isRetracted "false" @default.
• W2314906058 magId "2314906058" @default.
• W2314906058 workType "article" @default.